TY - JOUR
T1 - Symptom burden and medication use among patients with nontuberculous mycobacterial lung disease
AU - Pravosud, Vira
AU - Mannino, David M.
AU - Prieto, Delia
AU - Zhang, Quan
AU - Choate, Radmila
AU - Malanga, Elisha
AU - Aksamit, Timothy R.
N1 - Publisher Copyright:
© 2020 COPD Foundation. All rights reserved.
PY - 2020
Y1 - 2020
N2 - Purpose: Respiratory diseases caused by nontuberculous mycobacteria (NTM) have become a significant concern for patients and health care providers. We aimed to compare symptoms experienced during the 2-week period, at a single point in time, by patients with NTM lung disease (NTMLD) who were currently on any medication to treat their NTMLD versus those not on any therapies. Methods: We analyzed responses to a “Burden of NTM Survey” developed by the COPD Foundation. The study population included 266 individuals with NTMLD. Using adjusted penalized logistic regression models, we determined associations between the self-reported symptoms and the use of any medication to treat NTMLD. Results: Based on available data, most respondents were aged 50 and older (95.1%), of female gender (93.1%), and had been living with NTMLD for more than 5 years (55.7%). Many respondents reported symptoms that bother them very often or daily. After adjustment for age and gender, duration of living with NTMLD, and other respiratory illnesses, patients on medication had significantly larger odds of reporting difficulty in walking 500 meters without stopping, difficulty in interacting with others, fatigue or lack of energy, feelings of sadness or depression related to illness, and shortness of breath, wheezing or other difficulties. Conclusion: In this study, patients currently on any medication to treat their NTMLD reported more symptoms associated with their NTMLD. Further investigations are needed to explore whether increased symptoms are related to differences in disease severity and/or medication effects.
AB - Purpose: Respiratory diseases caused by nontuberculous mycobacteria (NTM) have become a significant concern for patients and health care providers. We aimed to compare symptoms experienced during the 2-week period, at a single point in time, by patients with NTM lung disease (NTMLD) who were currently on any medication to treat their NTMLD versus those not on any therapies. Methods: We analyzed responses to a “Burden of NTM Survey” developed by the COPD Foundation. The study population included 266 individuals with NTMLD. Using adjusted penalized logistic regression models, we determined associations between the self-reported symptoms and the use of any medication to treat NTMLD. Results: Based on available data, most respondents were aged 50 and older (95.1%), of female gender (93.1%), and had been living with NTMLD for more than 5 years (55.7%). Many respondents reported symptoms that bother them very often or daily. After adjustment for age and gender, duration of living with NTMLD, and other respiratory illnesses, patients on medication had significantly larger odds of reporting difficulty in walking 500 meters without stopping, difficulty in interacting with others, fatigue or lack of energy, feelings of sadness or depression related to illness, and shortness of breath, wheezing or other difficulties. Conclusion: In this study, patients currently on any medication to treat their NTMLD reported more symptoms associated with their NTMLD. Further investigations are needed to explore whether increased symptoms are related to differences in disease severity and/or medication effects.
UR - http://www.scopus.com/inward/record.url?scp=85106508953&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85106508953&partnerID=8YFLogxK
U2 - 10.15326/JCOPDF.2020.0184
DO - 10.15326/JCOPDF.2020.0184
M3 - Article
AN - SCOPUS:85106508953
VL - 8
SP - 243
EP - 254
JO - Chronic Obstructive Pulmonary Diseases
JF - Chronic Obstructive Pulmonary Diseases
IS - 2
ER -